(Reuters) – The biggest clinical trial so far to assess a new class of diabetes pills shows that AstraZeneca’s Farxiga can prevent heart failure and cut the risk of kidney problems in a broad range of patients. FILE PHOTO: A man walks past a sign at an AstraZeneca site in Macclesfield, central England May 19,… Read More: AstraZeneca's diabetes drug curbs heart failure, kidney risks »
Picture yourself playing tennis gowithstock/Shutterstock Or go play tennis. British researchers found volunteers trying to quit smoking were better able to ignore their urges to smoke when they were told to visualize a tennis match. Create a smoke-free zone Icatnews/Shutterstock Don’t allow anyone to use tobacco in your home, car, or even while sitting next… Read More: The 23 Best Ways to Quit Smoking »
By Robert Preidt HealthDay Reporter SATURDAY, Nov. 10, 2018 (HealthDay News) — The diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure, new research shows. Type 2 diabetics who took Farxiga (dapagliflozin) saw their odds of hospitalization for heart failure drop by 27 percent compared to those who… Read More: Diabetes Drug Might Also Ease Heart Failure Risks »
November 09, 2018 Share this content: Chloride sweat concentrations and Cystic Fibrosis Questionnaire-Revised scores improved when VX-659 was added to tezacaftor and ivacaftor. Patients with cystic fibrosis with either 1 or 2 Phe508del alleles who were treated with a drug combination of VX-659, tezacaftor, and ivacaftor showed improved forced expiratory volume in 1 second (FEV1),… Read More: Cystic Fibrosis Lung Function Improved With Triple Therapy »